136 related articles for article (PubMed ID: 3488319)
21. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
22. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.
Gorelik E; Wiltrout RH; Okumura K; Habu S; Herberman RB
Int J Cancer; 1982 Jul; 30(1):107-12. PubMed ID: 7118294
[TBL] [Abstract][Full Text] [Related]
23. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
24. "In vivo effects of rIL-2 pretreatment on chemotherapeutically induced in vivo natural cytolytic hyporesponsiveness".
Lockhart WL; Peacocke N; Ades EW
Immunopharmacol Immunotoxicol; 1987; 9(2-3):177-93. PubMed ID: 3501795
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy of murine hepatic metastases with lymphokine-activated killer cells expanded in serum-free media and recombinant interleukin 2.
Lafreniere R; Borkenhagen K; Bryant LD; Huchcroft S
Cancer Res; 1989 May; 49(9):2409-14. PubMed ID: 2565160
[TBL] [Abstract][Full Text] [Related]
26. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
Hinuma S; Naruo K; Ootsu K; Houkan T; Shiho O; Tsukamoto K
Immunology; 1987 Feb; 60(2):173-9. PubMed ID: 3493209
[TBL] [Abstract][Full Text] [Related]
27. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
28. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ.
Lala PK; Elkashab M; Kerbel RS; Parhar RS
Int Immunol; 1990; 2(12):1149-58. PubMed ID: 2090199
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 2-induced proliferation of murine natural killer cells in vivo.
Biron CA; Young HA; Kasaian MT
J Exp Med; 1990 Jan; 171(1):173-88. PubMed ID: 1688606
[TBL] [Abstract][Full Text] [Related]
30. Population dynamics of natural killer cells in the spleen and bone marrow of normal and leukemic mice during in vivo exposure to interleukin-2.
Christopher FL; Dussault I; Miller SC
Immunobiology; 1991 Dec; 184(1):37-52. PubMed ID: 1800310
[TBL] [Abstract][Full Text] [Related]
31. Comparative analysis of natural killer function in lung, spleen, and peripheral blood lymphocytes: evidence of differential characteristics.
Lauzon W; Yang H; Lemaire I
Reg Immunol; 1990-1991; 3(3):145-50. PubMed ID: 2129104
[TBL] [Abstract][Full Text] [Related]
32. Natural cytolytic activity in mice with natural or induced cellular defects. I. Differential ability of in vitro interleukin-2 addition to augment natural cytolytic function.
Ades EW; Hinson A; Butler LD
Cell Immunol; 1986 Aug; 101(1):15-23. PubMed ID: 3527446
[TBL] [Abstract][Full Text] [Related]
33. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma.
Silagi S; Dutkowski R; Schaefer A
Int J Cancer; 1988 Feb; 41(2):315-22. PubMed ID: 3123404
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.
Ootsu K; Gotoh K; Houkan T
Cancer Immunol Immunother; 1989; 30(2):71-80. PubMed ID: 2598180
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
[TBL] [Abstract][Full Text] [Related]
36. Recombinant interleukin-2 inhibits growth of human tumor xenografts in congenitally athymic mice.
Bubeník J; Kieler J; Tromholt V; Indrová M; Lotzová E
Immunol Lett; 1987 Apr; 14(4):325-30. PubMed ID: 3495490
[TBL] [Abstract][Full Text] [Related]
37. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
Rosenberg SA; Mulé JJ; Spiess PJ; Reichert CM; Schwarz SL
J Exp Med; 1985 May; 161(5):1169-88. PubMed ID: 3886826
[TBL] [Abstract][Full Text] [Related]
38. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
39. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver.
Wiltrout RH; Herberman RB; Zhang SR; Chirigos MA; Ortaldo JR; Green KM; Talmadge JE
J Immunol; 1985 Jun; 134(6):4267-75. PubMed ID: 3989307
[TBL] [Abstract][Full Text] [Related]
40. Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.
Ghosh AK; Mellor M; Prendiville J; Thatcher N
Br J Cancer; 1990 Mar; 61(3):471-4. PubMed ID: 2328217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
